Gelteq Ltd

Análisis de la acción Gelteq Ltd (GELS)

$0.440

-0.015 (-3.42%)Al cierre

Loading chart…
Máximo
0.460
Apertura
0.430
Precio medio ponderado por volumen
0.44
Volumen
24.68K
Capitalización
—
Mínimo
0.430
Importe
10.94K
EV/EBITDA, TTM
0.00

Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.

www.gelteq.com

Análisis de IA of Gelteq Ltd (GELS)

Vender

Gelteq Ltd is not a good buy right now due to its current price of $0.44, which is significantly below its 52-week high of $2.01, indicating a 78% decline. Additionally, the company has a negative gross margin of -707.96% and a current ratio of only 0.09, suggesting severe liquidity issues and operational challenges.

Métricas de valoración

El PER previsto actual de Gelteq Ltd (GELS) es 0.00, frente a su media de 5 años de 0.00.

PER previsto

Muy infravalorado
Media 5A P/E
0.00
P/E actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

EV/EBITDA previsto

Muy infravalorado
Media 5A EV/EBITDA
0.00
EV/EBITDA actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Precio/ventas previsto

Muy infravalorado
Media 5A P/S
0.00
P/S actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Escenarios de precio de Alphio AI para GELS

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%GELS

$2.04

Precio del escenario

B

Base

Base · 50%GELS

$1.83

Precio del escenario

B

Bajista

Bajista · 25%GELS

$1.61

Precio del escenario

Cronología de eventos

2026-02-11 (ET)

09:00:00

Gelteq and Healthy Extracts Sign Strategic Partnership MOU

2026-01-13 (ET)

09:20:00

Gelteq Oral Gel Platform Increases CBD Bioavailability by Over 22%

2025-12-16 (ET)

09:20:00

Gelteq Announces New Partnership with Hong Kong Flag Football Program

2025-12-09 (ET)

09:20:00

Gelteq Enters Three-Year Sales Agreement with Shenzhen Mana, Expected Revenue of $1.3 Million

2025-12-05 (ET)

10:50:00

Gelteq Announces Preclinical Findings Demonstrating Effectiveness of Gel Platform

Noticias

Preguntas frecuentes sobre GELS, respondidas por Alphio AI

Gelteq Limited is an Australia-based clinical and science-based company. The Company is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The Company offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The Company also offers a versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled. It operates in the Healthcare sector.

Gelteq Ltd is not a good buy right now due to its current price of $0.44, which is significantly below its 52-week high of $2.01, indicating a 78% decline. Additionally, the company has a negative gross margin of -707.96% and a current ratio of only 0.09, suggesting severe liquidity issues and operational challenges.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar